

North Central Cancer Treatment Group

N0682, A Phase II Clinical Trial of Denileukin Diftitox in Combination with Rituximab in Previously Untreated Follicular B-cell Non-Hodgkin's Lymphoma

Status Change Notice – April 19, 2010

NOTICE OF STATUS CHANGE

The Pre-Registration and Registration step of this study are **permanently closed** to patient accrual effective immediately. Patient entry will not be permitted after Monday, April 19, 2010.

Based on the interim analysis, two patients have died on this study, eight of the first 25 patients did not complete all therapy due to adverse events. Among those who finished therapy, the response rate is below the expectation. We feel this combination is too toxic and not sufficiently effective as a frontline therapy, and will therefore close the study.

Patients currently on study should remain on treatment at the discretion of the treating physician. Patients who remain on treatment should be followed according to the protocol.

Please retain this notice with the protocol.